KLRC1 and leukemia: Ruggeri L et al. found that immunodeficient mice coinfused with human primary leukemia or Epstein-Barr virus cell lines and NKG2A+ natural killer cells pretreated with antihuman NKG2A were rescued from disease progression [61].